{
  "id": 4601613,
  "title": "XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation",
  "url": "https://urgent.news/2026/08/31/xyra-announces-first-patient-dosed-in-europe-in-the-phase-2-3-harbor",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-31T08:03:57.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/xyra-announces-first-patient-dosed-in-europe-in-the-phase-2-3-harbor-af-study-of-budiodarone-in-paroxysmal-and-persistent-atrial-fibrillation"
  },
  "original_language": "en",
  "account": null,
  "summary": "LOS ALTOS, California, Aug. 31, 2026 (GLOBE NEWSWIRE) — Open-label, dose-escalation study using cardiac rhythm data from implantable and wearable AF monitors allows the treating physician to titrate the dose of budiodarone monthly. First European patient dosed in CLN-209 (HARBOR-AF) Study is the first to titrate an antiarrhythmic drug against continuously monitored AF burden (AFB) […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss",
        "url": "https://urgent.news/2026/08/30/tenax-finds-benefit-in-sicker-patient-subgroup-after-phase-3-trial",
        "published": "2026-08-30T19:01:28.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}